A5103024824- Congenital Heart Disease Studies
- Cardiac Valve Diseases and Treatments
- Cardiac Arrhythmias and Treatments
- Pulmonary Hypertension Research and Treatments
- Cardiovascular Conditions and Treatments
- Aortic Disease and Treatment Approaches
- Cardiac Structural Anomalies and Repair
- Cardiovascular and Diving-Related Complications
- Coronary Artery Anomalies
- Mechanical Circulatory Support Devices
- Infective Endocarditis Diagnosis and Management
- Cardiac Imaging and Diagnostics
- Central Venous Catheters and Hemodialysis
- Tracheal and airway disorders
- Cardiovascular Issues in Pregnancy
- Vascular anomalies and interventions
- Cardiovascular Function and Risk Factors
- Cardiac, Anesthesia and Surgical Outcomes
- Transplantation: Methods and Outcomes
- Congenital Diaphragmatic Hernia Studies
- Kawasaki Disease and Coronary Complications
- Renal and Vascular Pathologies
- Congenital heart defects research
- Cardiac pacing and defibrillation studies
- Radiation Dose and Imaging
The Ohio State University
2014-2025
Nationwide Children's Hospital
2015-2024
Toronto Public Health
2023
Stanford University
2015-2016
Johns Hopkins University
1991-2016
Medtronic (United States)
2016
Deutsches Herzzentrum München
2016
Deutsches Herzzentrum der Charité
2016
Beth Israel Deaconess Medical Center
2016
Piedmont Atlanta Hospital
2016
Background— Transcatheter pulmonary valve placement is an emerging therapy for regurgitation and right ventricular outflow tract obstruction in selected patients. The Melody was recently approved the United States dysfunctional conduits. Methods Results— From January 2007 to August 2009, 136 patients (median age, 19 years) underwent catheterization intended implantation at 5 centers. Implantation attempted 124 patients; other 12, transcatheter not because of risk coronary artery compression...
Background— Studies of transcatheter pulmonary valve (TPV) replacement with the Melody have demonstrated good short-term outcomes, but there are no published long-term follow-up data. Methods and Results— The US Investigational Device Exemption trial prospectively enrolled 171 pediatric adult patients (median age, 19 years) right ventricular outflow tract conduit obstruction or regurgitation. 148 who received were discharged a TPV followed up annually according to standardized protocol....
Background— Among patients undergoing transcatheter pulmonary valve (TPV) replacement with the Melody valve, risk factors for stent fracture (MSF) and right ventricular outflow tract (RVOT) reintervention have not been well defined. Methods Results— From January 2007 to 2010, 150 (median age, 19 years) underwent TPV implantation in Investigational Device Exemption trial. Existing conduit stents from a prior catheterization were present 37 (25%, fractured 12); 1 or more new prestents placed...
Background— The Melody transcatheter pulmonary valve (TPV) was approved for implantation in obstructed right ventricular outflow tract conduits 2010 after a multicenter trial demonstrating improvements conduit obstruction, regurgitation, and pressure. A recognized risk contraindication to TPV is the demonstration of coronary artery (CA) compression during balloon angioplasty or stent placement overlying conduit. This study first characterize CA this population. Methods Results— From 2007...
Background— Off-label use of transcatheter aortic and pulmonary valve prostheses for tricuspid valve-in-valve implantation (TVIV) within dysfunctional surgical (TV) bioprostheses has been described in small reports. Methods Results— An international, multicenter registry was developed to collect data on TVIV cases. Patient-related factors, procedural details outcomes, follow-up were analyzed. Valve-in-ring or heterotopic TV procedures not included. Data collected 156 patients with...
Seven boys with an apparently X-linked syndrome of dilated cardiomyopathy, growth retardation, neutropenia, and persistently elevated urinary levels 3-methylglutaconate, 3-methylglutarate, 2-ethylhydracrylate were studied. The natural history the disorder was characterized by severe or lethal cardiac disease recurrent infections during infancy early childhood but relative improvement in later childhood. initial presentation varied from congenital cardiomyopathy to infantile congestive heart...
Abstract Background: We report a multi‐institutional experience with intravascular stenting (IS) for treatment of coarctation the aorta. Methods and Results: Data was collected retrospectively by review medical records from 17 institutions. The data broken down to prior 2002 after further analysis. A total 565 procedures were performed median age 15 years (mean = 18.1 years). Successful reduction in post stent gradient (<20 mm Hg) or increase descending aorta (DAo) ratio >0.8 achieved...
To describe case mix variation among institutions, and report adverse event rates in congenital cardiac catheterization by type.Reported for patients with heart disease undergoing vary considerably, due to non-comparable standards of data inclusion, highly variable mix.The Congenital Cardiac Catheterization Outcomes Project (C3PO) has been capturing characteristics events (AE) all catheterizations performed at six pediatric institutions. Validity completeness were independently...
We report a multiinstitutional study on intermediate-term outcome of intravascular stenting for treatment coarctation the aorta using integrated arch imaging (IAI) techniques.Medical records 578 patients from 17 institutions were reviewed. A total 588 procedures performed between May 1989 and Aug 2005. About 27% (160/588) followed up by further IAI their (MRI/CT/repeat cardiac catheterization) after initial stent procedures. Abnormal studies included: presence dissection or aneurysm...
Abstract Introduction: Since the 1980s, stent implantation has evolved as an important therapeutic strategy for coarctation of aorta. However, available data is frequently flawed by short follow‐up, lack adequate follow‐up imaging, and retrospective nature collection. Methods : Data was prospectively collected using a multicenter registry congenital cardiovascular interventional study consortium (CCISC). Between 2000 2009, 302 patients from 34 centers with median weight 58 kg underwent...
Background— Transcatheter pulmonary valve implantation using the Melody has emerged as an important therapy for treatment of postoperative right ventricular outflow tract dysfunction. Melody-in-bioprosthetic valves (BPV) is currently considered off-label indication. We review combined experience with transcatheter within BPVs from 8 centers in United States and discuss technical aspects Melody-in-BPV procedure. Methods Results— A total 104 patients underwent position at US April 2007 to...
Background Percutaneous closure of patent ductus arteriosus ( PDA ) in term neonates is established, but data regarding outcomes infants born very preterm (<32 weeks gestation) are minimal, and no published criteria exist establishing a minimal weight 4 kg as suitable cutoff. We sought to analyze percutaneous occlusion referred for at weights <4 kg. Methods Results Retrospective analysis (January 2005–January 2014) was done single pediatric center. Procedural successes adverse events...
The Congenital Cardiac Catheterization Project on Outcomes (C3PO) was established to develop outcome assessment methods for pediatric catheterization.Six sites have been recording demographic, procedural and immediate data all cases, using a web-based system since February 2007. A sample of independently audited validity completeness. In 2006, participants categorized 84 procedure types into 6 categories by anticipated risk an adverse event (AE). Consensus empirical were used determine final...
Melody Transcatheter Pulmonary Valve (TPV) replacement therapy represents an important advance in congenital cardiovascular interventions. The off-label extension of the TPV to patients with nonconduit outflow tracts (right ventricular tract [RVOT]) has potential vastly expand population eligible benefit from nonsurgical restoration RVOT function. However, knowledge on performance this setting is limited.This a multicenter, retrospective review when placed RVOTs, which at least portion...
We developed a tissue-engineered vascular graft (TEVG) for use in children and present results of U.S. Food Drug Administration (FDA)-approved clinical trial evaluating this patients with single-ventricle cardiac anomalies. The TEVG was used as Fontan conduit to connect the inferior vena cava pulmonary artery, but high incidence narrowing manifested within first 6 months, which treated successfully angioplasty. To elucidate mechanisms underlying early stenosis, we data-informed,...
The risk for stroke after transcatheter aortic valve replacement (TAVR) is an important concern. Identification of predictors likely to be a critical factor aiding patient selection and management as TAVR use becomes widespread.Patients enrolled in the CoreValve US Extreme Risk High Pivotal Trials or Continued Access Study treated with self-expanding bioprosthesis were included this analysis. 1-year rate was 8.4%. Analysis hazard identified early phase (0-10 days; 4.1% strokes) late (11-365...